A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation

Journal of Immunology

Volumn 185, Issue 7, 2010, Pages 3919-3931

  Haidinger, Michael ^a   Poglitsch, Marko ^a   Geyeregger, Rene ^c   Kasturi, Sudhir ^d   Zeyda, Maximilian ^a   Zlabinger, Gerhard J ^b   Pulendran, Bali ^d   Hörl, Walter H ^a   Säemann, Marcus D ^a   Weichhart, Thomas ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c St Anna Children's Cancer Research Institute   (Austria)

^d EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CD86 ANTIGEN; CYCLOSPORIN A; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHATIDYLINOSITOL 3 KINASE; PREDNISONE; PROGRAMMED DEATH 1 LIGAND 1; RAPAMYCIN; STAT3 PROTEIN; TACROLIMUS; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE;

ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FATE; CELL FUNCTION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNOREGULATION; IN VIVO STUDY; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MONOCYTE DERIVED DENDRITIC CELL; MYELOID DENDRITIC CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; T LYMPHOCYTE; BIOSYNTHESIS; CELL SEPARATION; CYTOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

CELL DIFFERENTIATION; CELL SEPARATION; CYTOKINES; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY TRANSPLANTATION; MALE; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; NF-KAPPA B; PROTEIN-SERINE-THREONINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 77958126087     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1000296     Document Type: Article

References (67)

1. Kapsenberg, M. L. 2003. Dendritic-cell control of pathogen-driven T-cell polarization. Nat. Rev. Immunol. 3:984-993.
2. Shortman, K., and Y. J. Liu. 2002. Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. 2:151-161.
3. MacDonald, K. P., D. J. Munster, G. J. Clark, A. Dzionek, J. Schmitz, and D. N. Hart. 2002. Characterization of human blood dendritic cell subsets. Blood 100:4512-4520.
4. Gilliet, M., W. Cao, and Y. J. Liu. 2008. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat. Rev. Immunol. 8:594-606.
5. Zhu, J., H. Yamane, and W. E. Paul. 2010. Differentiation of effector CD4 T cell populations (*). Annu. Rev. Immunol. 28:445-489.
6. Kiertscher, S. M., and M. D. Roth. 1996. Human CD14+ leukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4. J. Leukoc. Biol. 59:208-218.
7. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179:1109-1118.
8. Xu, Y., Y. Zhan, A. M. Lew, S. H. Naik, and M. H. Kershaw. 2007. Differential development of murine dendritic cells by GM-CSF versus Flt3 ligand has implications for inflammation and trafficking. J. Immunol. 179:7577-7584.
9. Krutzik, S. R., B. Tan, H. Li, M. T. Ochoa, P. T. Liu, S. E. Sharfstein, T. G. Graeber, P. A. Sieling, Y. J. Liu, T. H. Rea, et al. 2005. TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells. Nat. Med. 11:653-660.
10. Sebastián, C., M. Serra, A. Yeramian, N. Serrat, J. Lloberas, and A. Celada. 2008. Deacetylase activity is required for STAT5-dependent GM-CSF functional activity in macrophages and differentiation to dendritic cells. J. Immunol. 180:5898-5906.
11. Yang, Q., and K. L. Guan. 2007. Expanding mTOR signaling. Cell Res. 17:666-681.
12. Dann, S. G., A. Selvaraj, and G. Thomas. 2007. mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol. Med. 13:252-259.
13. Weichhart, T., and M. D. Säemann. 2009. The multiple facets of mTOR in immunity. Trends Immunol. 30:218-226.
14. Thoreen, C. C., S. A. Kang, J. W. Chang, Q. Liu, J. Zhang, Y. Gao, L. J. Reichling, T. Sim, D. M. Sabatini, and N. S. Gray. 2009. An ATP-competitive mTOR inhibitor reveals rapamycin-insensitive functions of mTORC1. J. Biol. Chem. 284:8023-8032.
15. Brugarolas, J., and W. G. Kaelin, Jr. 2004. Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell 6:7-10.
16. Rini, B. I., W. K. Rathmell, and P. Godley. 2008. Renal cell carcinoma. Curr. Opin. Oncol. 20:300-306.
17. Bissler, J. J., F. X. McCormack, L. R. Young, J. M. Elwing, G. Chuck, J. M. Leonard, V. J. Schmithorst, T. Laor, A. S. Brody, J. Bean, et al. 2008. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 358:140-151.
18. Haidinger, M., M. Hecking, T. Weichhart, M. Poglitsch, W. Enkner, K. Vonbank, D. Prayer, A. Geusau, R. Oberbauer, G. J. Zlabinger, et al. 2010. Sirolimus in renal transplant recipients with tuberous sclerosis complex: clinical effectiveness and implications for innate immunity. Transpl Int. 23:777-785.
19. Edelstein, C. L. 2008. Mammalian target of rapamycin and caspase inhibitors in polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 3:1219-1226.
20. Delgoffe, G. M., T. P. Kole, Y. Zheng, P. E. Zarek, K. L. Matthews, B. Xiao, P. F. Worley, S. C. Kozma, and J. D. Powell. 2009. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 30:832-844.
21. Battaglia, M., A. Stabilini, and M. G. Roncarolo. 2005. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 105:4743-4748.
22. Araki, K., A. P. Turner, V. O. Shaffer, S. Gangappa, S. A. Keller, M. F. Bachmann, C. P. Larsen, and R. Ahmed. 2009. mTOR regulates memory CD8 T-cell differentiation. Nature 460:108-112.
23. Hackstein, H., T. Taner, A. F. Zahorchak, A. E. Morelli, A. J. Logar, A. Gessner, and A. W. Thomson. 2003. Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 101:4457-4463.
24. Thomson, A. W., H. R. Turnquist, and G. Raimondi. 2009. Immunoregulatory functions of mTOR inhibition. Nat. Rev. Immunol. 9:324-337.
25. Woltman, A. M., J. W. de Fijter, S. W. Kamerling, S. W. van der Kooij, L. C. Paul, M. R. Daha, and C. van Kooten. 2001. Rapamycin induces apoptosis in monocyte-and CD34-derived dendritic cells but not in monocytes and macrophages. Blood 98:174-180.
26. Woltman, A. M., S. W. van der Kooij, P. J. Coffer, R. Offringa, M. R. Daha, and C. van Kooten. 2003. Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. Blood 101:1439-1445.
27. Hackstein, H., T. Taner, A. J. Logar, and A. W. Thomson. 2002. Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood 100:1084-1087.
28. Monti, P., A. Mercalli, B. E. Leone, D. C. Valerio, P. Allavena, and L. Piemonti. 2003. Rapamycin impairs antigen uptake of human dendritic cells. Transplantation 75:137-145.
29. Singer, S. J., R. Tiernan, and E. J. Sullivan. 2000. Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N. Engl. J. Med. 343:1815-1816.
30. Dittrich, E., S. Schmaldienst, A. Soleiman, W. H. Hörl, and E. Pohanka. 2004. Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transpl. Int. 17:215-220.
31. Izzedine, H., I. Brocheriou, and C. Frances. 2005. Post-transplantation proteinuria and sirolimus. N. Engl. J. Med. 353:2088-2089.
32. Thaunat, O., C. Beaumont, L. Chatenoud, S. Lechaton, M. F. Mamzer-Bruneel, B. Varet, H. Kreis, and E. Morelon. 2005. Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state. Transplantation 80:1212-1219.
33. Ohtani, M., S. Nagai, S. Kondo, S. Mizuno, K. Nakamura, M. Tanabe, T. Takeuchi, S. Matsuda, and S. Koyasu. 2008. Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharideinduced interleukin-12 production in dendritic cells. Blood 112:635-643.
34. Weichhart, T., G. Costantino, M. Poglitsch, M. Rosner, M. Zeyda, K. M. Stuhlmeier, T. Kolbe, T. M. Stulnig, W. H. Hörl, M. Hengstschläger, et al. 2008. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 29:565-577.
35. Yang, C. S., C. H. Song, J. S. Lee, S. B. Jung, J. H. Oh, J. Park, H. J. Kim, J. K. Park, T. H. Paik, and E. K. Jo. 2006. Intracellular network of phosphatidylinositol 3-kinase, mammalian target of the rapamycin/70 kDa ribosomal S6 kinase 1, and mitogen-activated protein kinases pathways for regulating mycobacteria-induced IL-23 expression in human macrophages. Cell. Microbiol. 8:1158-1171.
36. Säemann, M. D., T. Weichhart, M. Zeyda, G. Staffler, M. Schunn, K. M. Stuhlmeier, Y. Sobanov, T. M. Stulnig, S. Akira, A. von Gabain, et al. 2005. Tamm-Horsfall glycoprotein links innate immune cell activation with adaptive immunity via a Toll-like receptor-4-dependent mechanism. J. Clin. Invest. 115:468-475.
37. Cao, W., S. Manicassamy, H. Tang, S. P. Kasturi, A. Pirani, N. Murthy, and B. Pulendran. 2008. Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI (3) K-mTOR-p70S6K pathway. Nat. Immunol. 9:1157-1164.
38. Greenwald, R. J., G. J. Freeman, and A. H. Sharpe. 2005. The B7 family revisited. Annu. Rev. Immunol. 23:515-548.
39. Ghosh, S., V. Tergaonkar, C. V. Rothlin, R. G. Correa, V. Bottero, P. Bist, I. M. Verma, and T. Hunter. 2006. Essential role of tuberous sclerosis genes TSC1 and TSC2 in NF-kappaB activation and cell survival. Cancer Cell 10:215-226.
40. Minhajuddin, M., F. Fazal, K. M. Bijli, M. R. Amin, and A. Rahman. 2005. Inhibition of mammalian target of rapamycin potentiates thrombin-induced intercellular adhesion molecule-1 expression by accelerating and stabilizing NF-kappa B activation in endothelial cells. J. Immunol. 174:5823-5829.
41. Gupta, A., C. Ashokkumar, M. Ningappa, Q. Sun, B. W. Higgs, S. Snyder, M. Johnson, A. Zeevi, K. M. Abu-Elmagd, A. W. Thomson, et al. 2010. Elevated myeloid: plasmacytoid dendritic cell ratio associates with early acute cellular rejection in pediatric small bowel transplantation. Transplantation 89:55-60.
42. Mazariegos, G. V., A. F. Zahorchak, J. Reyes, L. Ostrowski, B. Flynn, A. Zeevi, and A. W. Thomson. 2003. Dendritic cell subset ratio in peripheral blood correlates with successful withdrawal of immunosuppression in liver transplant patients. Am. J. Transplant. 3:689-696.
43. Ma, W., K. Gee, W. Lim, K. Chambers, J. B. Angel, M. Kozlowski, and A. Kumar. 2004. Dexamethasone inhibits IL-12p40 production in lipopolysaccharidestimulated human monocytic cells by down-regulating the activity of c-Jun. N-terminal kinase, the activation protein-1, and NF-kappa B transcription factors. J. Immunol. 172:318-330.
44. Piemonti, L., P. Monti, P. Allavena, M. Sironi, L. Soldini, B. E. Leone, C. Socci, and V. Di Carlo. 1999. Glucocorticoids affect human dendritic cell differentiation and maturation. J. Immunol. 162:6473-6481.
45. Xia, C. Q., R. Peng, F. Beato, and M. J. Clare-Salzler. 2005. Dexamethasone induces IL-10-producing monocyte-derived dendritic cells with durable immaturity. Scand. J. Immunol. 62:45-54.
46. Cohen, N., E. Mouly, H. Hamdi, M. C. Maillot, M. Pallardy, V. Godot, F. Capel, A. Balian, S. Naveau, P. Galanaud, et al. 2006. GILZ expression in human dendritic cells redirects their maturation and prevents antigen-specific T lymphocyte response. Blood 107:2037-2044.
47. Woltman, A. M., S. W. van der Kooij, J. W. de Fijter, and C. van Kooten. 2006. Maturation-resistant dendritic cells induce hyporesponsiveness in alloreactive CD45RA+ and CD45RO+ T-cell populations. Am. J. Transplant. 6:2580-2591.
48. Tokita, D., G. V. Mazariegos, A. F. Zahorchak, N. Chien, M. Abe, G. Raimondi, and A. W. Thomson. 2008. High PD-L1/CD86 ratio on plasmacytoid dendritic cells correlates with elevated T-regulatory cells in liver transplant tolerance. Transplantation 85:369-377.
49. Fukao, T., M. Tanabe, Y. Terauchi, T. Ota, S. Matsuda, T. Asano, T. Kadowaki, T. Takeuchi, and S. Koyasu. 2002. PI3K-mediated negative feedback regulation of IL-12 production in DCs. Nat. Immunol. 3:875-881.
50. Schmitz, F., A. Heit, S. Dreher, K. Eisenächer, J. Mages, T. Haas, A. Krug, K. P. Janssen, C. J. Kirschning, and H. Wagner. 2008. Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells. Eur. J. Immunol. 38:2981-2992.
51. Sordi, V., G. Bianchi, C. Buracchi, A. Mercalli, F. Marchesi, G. D'Amico, C. H. Yang, W. Luini, A. Vecchi, A. Mantovani, et al. 2006. Differential effects of immunosuppressive drugs on chemokine receptor CCR7 in human monocyte-derived dendritic cells: selective upregulation by rapamycin. Transplantation 82:826-834.
52. Horibe, E. K., J. Sacks, J. Unadkat, G. Raimondi, Z. Wang, R. Ikeguchi, D. Marsteller, L. M. Ferreira, A. W. Thomson, W. P. Lee, and M. Feili-Hariri. 2008. Rapamycin-conditioned, alloantigen-pulsed dendritic cells promote indefinite survival of vascularized skin allografts in association with T regulatory cell expansion. Transpl. Immunol. 18:307-318.
53. Weichhart, T., and M. D. Säemann. 2008. The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications. Ann. Rheum. Dis. 67 (Suppl 3): iii70-iii74.
54. Turnquist, H. R., G. Raimondi, A. F. Zahorchak, R. T. Fischer, Z. Wang, and A. W. Thomson. 2007. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J. Immunol. 178:7018-7031.
55. Säemann, M. D., M. Haidinger, M. Hecking, W. H. Hörl, and T. Weichhart. 2009. The multifunctional role of mTOR in innate immunity: implications for transplant immunity. Am. J. Transplant. 9:2655-2661.
56. Jagannath, C., D. R. Lindsey, S. Dhandayuthapani, Y. Xu, R. L. Hunter, Jr., and N. T. Eissa. 2009. Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells. Nat. Med. 15:267-276.
57. Willmann, K., and J. F. Dunne. 2000. A flow cytometric immune function assay for human peripheral blood dendritic cells. J. Leukoc. Biol. 67:536-544.
58. Ida, J. A., N. Shrestha, S. Desai, S. Pahwa, W. A. Hanekom, and P. A. Haslett. 2006. A whole blood assay to assess peripheral blood dendritic cell function in response to Toll-like receptor stimulation. J. Immunol. Methods 310:86-99.
59. Hodge, S., G. Hodge, R. Flower, and P. Han. 2000. Surface and intracellular interleukin-2 receptor expression on various resting and activated populations involved in cell-mediated immunity in human peripheral blood. Scand. J. Immunol. 51:67-72.
60. Lehman, J. A., V. Calvo, and J. Gomez-Cambronero. 2003. Mechanism of ribosomal p70S6 kinase activation by granulocyte macrophage colony-stimulating factor in neutrophils: cooperation of a MEK-related, THR421/SER424 kinase and a rapamycin-sensitive, m-TOR-related THR389 kinase. J. Biol. Chem. 278:28130-28138.
61. Taner, T., H. Hackstein, Z. Wang, A. E. Morelli, and A. W. Thomson. 2005. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival. Am. J. Transplant. 5:228-236.
62. Kusaba, H., P. Ghosh, R. Derin, M. Buchholz, C. Sasaki, K. Madara, and D. L. Longo. 2005. Interleukin-12-induced interferon-gamma production by human peripheral blood T cells is regulated by mammalian target of rapamycin (mTOR). J. Biol. Chem. 280:1037-1043.
63. Zhou, J., J. Wulfkuhle, H. Zhang, P. Gu, Y. Yang, J. Deng, J. B. Margolick, L. A. Liotta, E. Petricoin, III, and Y. Zhang. 2007. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc. Natl. Acad. Sci. USA 104:16158-16163.
64. Laouar, Y., T. Welte, X. Y. Fu, and R. A. Flavell. 2003. STAT3 is required for Flt3L-dependent dendritic cell differentiation. Immunity 19:903-912.
65. Ma, J., Y. Meng, D. J. Kwiatkowski, X. Chen, H. Peng, Q. Sun, X. Zha, F. Wang, Y. Wang, Y. Jing, et al. 2010. Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade. J. Clin. Invest. 120:103-114.
66. Letavernier, E., P. Bruneval, C. Mandet, J. P. Duong Van Huyen, M. N. Péraldi, I. Helal, L. H. Noël, and C. Legendre. 2007. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin. J. Am. Soc. Nephrol. 2:326-333.
67. Jørgensen, P. F., J. E. Wang, M. Almlöf, R. Solberg, C. Okkenhaug, T. Scholz, C. Thiemermann, S. J. Foster, and A. O. Aasen. 2001. Sirolimus interferes with the innate response to bacterial products in human whole blood by attenuation of IL-10 production. Scand. J. Immunol. 53:184-191.